Gabor G Kovacs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9020275/publications.pdf

Version: 2024-02-01

340 papers	19,659 citations	11608 70 h-index	16605 123 g-index

369 all docs	369 docs citations	369 times ranked	18145 citing authors

#	Article	IF	Citations
1	Current Concepts of Mixed Pathologies in Neurodegenerative Diseases. Canadian Journal of Neurological Sciences, 2023, 50, 329-345.	0.3	22
2	The spectrum of disease and tau pathology of nodding syndrome in Uganda. Brain, 2023, 146, 954-967.	3.7	8
3	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. Brain, 2022, 145, 700-712.	3.7	16
4	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	3.9	19
5	Combining Skin Î±â€Synuclein <scp>Realâ€Time Quakingâ€Induced Conversion</scp> and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease. Movement Disorders, 2022, 37, 648-650.	2.2	12
6	Cryo-EM structures of amyloid-Î² 42 filaments from human brains. Science, 2022, 375, 167-172.	6.0	228
7	Classification of diseases with accumulation of Tau protein. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	32
8	Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy. Translational Neurodegeneration, 2022, 11, 7.	3.6	42
9	Patterns of Mixed Pathologies in Down Syndrome. Journal of Alzheimer's Disease, 2022, 87, 595-607.	1.2	8
10	Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature, 2022, 605, 310-314.	13.7	88
11	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	5.8	34
12	Enhanced expression of autophagyâ€related p62 without increased deposits of neurodegenerationâ€associated proteins in glioblastoma and surrounding tissue â€“ An autopsyâ€based study. Brain Pathology, 2022, 32, e13058.	2.1	5
13	Protracted course progressive supranuclear palsy. European Journal of Neurology, 2022, 29, 2220-2231.	1.7	8
14	Detection of astrocytic tau pathology facilitates recognition of chronic traumatic encephalopathy neuropathologic change. Acta Neuropathologica Communications, 2022, 10, 50.	2.4	13
15	Î±-Synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders. Acta Neuropathologica, 2022, 144, 167-185.	3.9	12
16	Frequency of LATE neuropathologic change across the spectrum of Alzheimerâ€™s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathologica, 2022, 144, 27-44.	3.9	67
17	A novel temporalâ€predominantÂneuroâ€astroglial tauopathyÂassociated with TMEM106B gene polymorphism in FTLD/ALSâ€TDP. Brain Pathology, 2021, 31, 267-282.	2.1	12
18	Multiple system agingâ€related tau astrogliopathy with complex proteinopathy in an oligosymptomatic octogenarian. Neuropathology, 2021, 41, 72-83.	0.7	11

#	Article	IF	Citations
19	Coâ€incidental C9orf72 expansion mutationâ€related frontotemporal lobar degeneration pathology and sporadic Creutzfeldtâ^'Jakob disease. European Journal of Neurology, 2021, 28, 1009-1015.	1.7	2
20	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 102-111.	0.9	35
21	Astrocytic-Neuronal Teamwork Against External Iron Attacks: Does It Always Work?. Function, 2021, 2, zqab009.	1.1	0
22	COllaborative Neuropathology NEtwork Characterizing ouTcomes of TBI (CONNECT-TBI). Acta Neuropathologica Communications, 2021, 9, 32.	2.4	13
23	Dream Enactment Behavior Disorder Associated with Pallidoâ€Nigroâ€Luysian Degeneration and Tau Proteinopathy. Movement Disorders Clinical Practice, 2021, 8, 594-599.	0.8	2
24	Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurology, The, 2021, 20, 235-246.	4.9	151
25	Corpus Callosum Hyperintensity in Normal Pressure Hydrocephalus After Ventriculoperitoneal Shunt. Neurology, 2021, 96, 1096-1097.	1.5	1
26	AÎ²43 aggregates exhibit enhanced prion-like seeding activity in mice. Acta Neuropathologica Communications, 2021, 9, 83.	2.4	14
27	Neurodegenerative proteinopathies associated with neuroinfections. Journal of Neural Transmission, 2021, 128, 1551-1566.	1.4	17
28	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. International Journal of Molecular Sciences, 2021, 22, 7292.	1.8	7
29	Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study. Acta Neuropathologica Communications, 2021, 9, 134.	2.4	32
30	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nature Reviews Neurology, 2021, 17, 601-620.	4.9	41
31	The Discovery of Î±â€Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. Movement Disorders Clinical Practice, 2021, 8, 1189-1193.	0.8	1
32	Association Between Globular Glial Tauopathies and Frontotemporal Dementiaâ€"Expanding the Spectrum of Gliocentric Disorders. JAMA Neurology, 2021, 78, 1004.	4.5	16
33	Structure-based classification of tauopathies. Nature, 2021, 598, 359-363.	13.7	409
34	Histotype-Dependent Oligodendroglial PrP Pathology in Sporadic CJD: A Frequent Feature of the M2C â€œStrainâ€. Viruses, 2021, 13, 1796.	1.5	1
35	Variable expression of mitochondrial complex IV in the course of nigral intracellular accumulation of Î±-synuclein. Parkinsonism and Related Disorders, 2021, 90, 57-61.	1.1	3
36	Neuropathological Variability within a Spectrum of <scp>NMDAR</scp>â€Encephalitis. Annals of Neurology, 2021, 90, 725-737.	2.8	35

#	Article	IF	Citations
37	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathologica, 2021, 141, 159-172.	3.9	107
38	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	2.2	37
39	Predominant neurological phenotype in a Hungarian family with two novel mutations in the XPA geneâ€"case series. Neurological Sciences, 2020, 41, 125-129.	0.9	4
40	Novel dominant MPAN family with a complex genetic architecture as a basis for phenotypic variability. Neurology: Genetics, 2020, 6, e515.	0.9	9
41	Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the ATP6V1B2 Gene. Frontiers in Neurology, 2020, 11, 767.	1.1	9
42	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	1.7	38
43	Practical Considerations in the Diagnosis of Mild Chronic Traumatic Encephalopathy and Distinction From Age-Related Tau Astrogliopathy. Journal of Neuropathology and Experimental Neurology, 2020, 79, 921-924.	0.9	12
44	Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots. Journal of Clinical Medicine, 2020, 9, 2234.	1.0	10
45	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	4.9	42
46	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	3.9	210
47	The autophagic marker p62 highlights Alzheimer type II astrocytes in metabolic/hepatic encephalopathy. Neuropathology, 2020, 40, 358-366.	0.7	4
48	Argyrophilic grain disease in individuals younger than 75 years: clinical variability in an underâ€recognized limbic tauopathy. European Journal of Neurology, 2020, 27, 1856-1866.	1.7	13
49	Thorn-shaped astrocytes in the depth of cortical sulci in Western Pacific ALS/Parkinsonism-Dementia complex. Acta Neuropathologica, 2020, 140, 591-593.	3.9	4
50	Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease. Biomolecules, 2020, 10, 290.	1.8	10
51	Proteomics-Enriched Prediction Model for Poor Neurologic Outcome in Cardiac Arrest Survivors*. Critical Care Medicine, 2020, 48, 167-175.	0.4	16
52	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	3.9	15
53	Astroglia and Tau: New Perspectives. Frontiers in Aging Neuroscience, 2020, 12, 96.	1.7	73
54	Mitochondrial respiratory chain deficiency correlates with the severity of neuropathology in sporadic Creutzfeldt-Jakob disease. Acta Neuropathologica Communications, 2020, 8, 50.	2.4	14

#	Article	IF	Citations
55	CpG and non-CpG Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated with gene expression in human and murine brain. Epigenetics, 2020, 15, 781-799.	1.3	39
56	Molecular pathology of neurodegenerative diseases: principles and practice. Journal of Clinical Pathology, 2019, 72, 725-735.	1.0	130
57	Reply: LATE to the PART-y. Brain, 2019, 142, e48-e48.	3.7	11
58	Alterations in GABAA Receptor Subunit Expression in the Amygdala and Entorhinal Cortex in Human Temporal Lobe Epilepsy. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1022-1048.	0.9	8
59	Î±â€Synuclein RTâ€QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Annals of Clinical and Translational Neurology, 2019, 6, 2120-2126.	1.7	87
60	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. Translational Neurodegeneration, 2019, 8, 28.	3.6	70
61	Secretagogin expression in the vertebrate brainstem with focus on the noradrenergic system and implications for Alzheimerâ€™s disease. Brain Structure and Function, 2019, 224, 2061-2078.	1.2	14
62	Four-repeat tauopathies. Progress in Neurobiology, 2019, 180, 101644.	2.8	141
63	Experimental Motor Neuron Disease Induced in Mice with Long-Term Repeated Intraperitoneal Injections of Serum from ALS Patients. International Journal of Molecular Sciences, 2019, 20, 2573.	1.8	11
64	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	3.7	873
65	Identification of odors, faces, cities and naming of objects in patients with subjective cognitive decline, mild cognitive impairment and AlzheimerÂ´s disease: a longitudinal study. International Psychogeriatrics, 2019, 31, 537-549.	0.6	22
66	Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases?. Current Opinion in Neurology, 2019, 32, 279-291.	1.8	30
67	Pyramidal system involvement in progressive supranuclear palsy â€“ a clinicopathological correlation. BMC Neurology, 2019, 19, 42.	0.8	8
68	Chronic Traumatic Encephalopathy (CTE) Is Absent From a European Community-Based Aging Cohort While Cortical Aging-Related Tau Astrogliopathy (ARTAG) Is Highly Prevalent. Journal of Neuropathology and Experimental Neurology, 2019, 78, 398-405.	0.9	43
69	Accumulation of prion protein in the vagus nerve in creutzfeldtâ€“jakob disease. Annals of Neurology, 2019, 85, 782-787.	2.8	12
70	A walk through tau therapeutic strategies. Acta Neuropathologica Communications, 2019, 7, 22.	2.4	211
71	Globular Glial Tauopathy Type I Presenting as Atypical Progressive Aphasia, With Comorbid Limbic-Predominant Age-Related TDP-43 Encephalopathy. Frontiers in Aging Neuroscience, 2019, 11, 336.	1.7	8
72	Neuropathology-driven Whole-genome Sequencing Study Points to Novel Candidate Genes for Healthy Brain Aging. Alzheimer Disease and Associated Disorders, 2019, 33, 7-14.	0.6	1

#	Article	IF	Citations
73	Corticobasal degeneration. International Review of Neurobiology, 2019, 149, 87-136.	0.9	24
74	Brain-wide genetic mapping identifies the indusium griseum as a prenatal target of pharmacologically unrelated psychostimulants. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25958-25967.	3.3	12
75	Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients. Biomolecules, 2019, 9, 800.	1.8	8
76	Atypical parkinsonism of progressive supranuclear palsyâ€“parkinsonism (PSP-P) phenotype with rare variants in FBXO7 and VPS35 genes associated with Lewy body pathology. Acta Neuropathologica, 2019, 137, 171-173.	3.9	18
77	Macrophagic scavenging of AÎ². , 2019, 38, 48-50.		0
78	Lysosomal response in relation to Î±-synuclein pathology differs between Parkinson's disease and multiple system atrophy. Neurobiology of Disease, 2018, 114, 140-152.	2.1	13
79	Concepts and classification of neurodegenerative diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 301-307.	1.0	109
80	Tauopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 355-368.	1.0	156
81	Hippocampal Radial Glial Subtypes and Their Neurogenic Potential in Human Fetuses and Healthy and Alzheimerâ€™s Disease Adults. Cerebral Cortex, 2018, 28, 2458-2478.	1.6	128
82	Filamentous Aggregation of Sequestosome-1/p62 in Brain Neurons and Neuroepithelial Cells upon Tyr-Cre-Mediated Deletion of the Autophagy Gene Atg7. Molecular Neurobiology, 2018, 55, 8425-8437.	1.9	13
83	Tauopathy with hippocampal 4â€repeat tau immunoreactive spherical inclusions: a report of three cases. Brain Pathology, 2018, 28, 274-283.	2.1	12
84	Alzheimer neuropathology without frontotemporal lobar degeneration hallmarks (<scp>TAR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 T<scp>C</scp>ys139<scp>A</scp>rg. Brain Pathology, 2018, 28, 72-76.	2.1	16
85	The physiological phosphorylation of tau is critically changed in fetal brains of individuals with Down syndrome. Neuropathology and Applied Neurobiology, 2018, 44, 314-327.	1.8	22
86	Connexinâ€43 and aquaporinâ€4 are markers of ageingâ€related tau astrogliopathy (ARTAG)â€related astroglial response. Neuropathology and Applied Neurobiology, 2018, 44, 491-505.	1.8	29
87	GABA_A receptor subunits in the human amygdala and hippocampus: Immunohistochemical distribution of 7 subunits. Journal of Comparative Neurology, 2018, 526, 324-348.	0.9	35
88	Prevalence of transactive response DNAâ€binding protein 43 (TDPâ€43) proteinopathy in cognitively normal older adults: systematic review and metaâ€analysis. Neuropathology and Applied Neurobiology, 2018, 44, 286-297.	1.8	25
89	Understanding the Relevance of Aging-Related Tau Astrogliopathy (ARTAG). Neuroglia (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.8	7
90	Prediction of Autopsy Verified Neuropathological Change of Alzheimerâ€™s Disease Using Machine Learning and MRI. Frontiers in Aging Neuroscience, 2018, 10, 406.	1.7	26

#	Article	IF	Citations
91	Non-motor Behavioral Alterations of PGC-1Î±-Deficient Mice â€“ A Peculiar Phenotype With Slight Male Preponderance and No Apparent Progression. Frontiers in Behavioral Neuroscience, 2018, 12, 180.	1.0	9
92	Î±â€Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa. Movement Disorders, 2018, 33, 1366-1368.	2.2	12
93	Alpha-synuclein Aggregates in Labial Salivary Glands of Idiopathic Rapid Eye Movement Sleep Behavior Disorder. Sleep, 2018, 41, .	0.6	18
94	Cellular reactions of the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 13-23.	1.0	22
95	Comorbidities. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 573-577.	1.0	4
96	Prion replication environment defines the fate of prion strain adaptation. PLoS Pathogens, 2018, 14, e1007093.	2.1	19
97	Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain. Acta Neuropathologica Communications, 2018, 6, 50.	2.4	77
98	Microglia control the spread of neurotropic virus infection via P2Y12 signalling and recruit monocytes through P2Y12-independent mechanisms. Acta Neuropathologica, 2018, 136, 461-482.	3.9	108
99	Hemoglobin mRNA Changes in the Frontal Cortex of Patients with Neurodegenerative Diseases. Frontiers in Neuroscience, 2018, 12, 8.	1.4	26
100	Preface. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, ix.	1.0	1
101	Co-aggregation of pro-inflammatory S100A9 with Î±-synuclein in Parkinsonâ€™s disease: ex vivo and in vitro studies. Journal of Neuroinflammation, 2018, 15, 172.	3.1	50
102	S100A9-Driven Amyloid-Neuroinflammatory Cascade in Traumatic Brain Injury as a Precursor State for Alzheimerâ€™s Disease. Scientific Reports, 2018, 8, 12836.	1.6	38
103	Regenerating islet-derived 1Î± (REG-1Î±) protein increases tau phosphorylation in cell and animal models of tauopathies. Neurobiology of Disease, 2018, 119, 136-148.	2.1	11
104	New classification of tauopathies. Revue Neurologique, 2018, 174, 664-668.	0.6	39
105	Genetic Creutzfeldtâ€“Jakob disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 219-242.	1.0	41
106	Non-Alzheimerâ€™s contributions to dementia and cognitive resilience in The 90+ Study. Acta Neuropathologica, 2018, 136, 377-388.	3.9	112
107	Mitochondrial diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 147-155.	1.0	44
108	Clinical Neuropathology image 6-2018: Metastasis of breast carcinoma to meningioma. , 2018, 37, 252-253.		3

#	Article	IF	Citations
109	Secretagogin-dependent matrix metalloprotease-2 release from neurons regulates neuroblast migration. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2006-E2015.	3.3	27
110	Visualization of neuritic plaques in Alzheimerâ€™s disease by polarization-sensitive optical coherence microscopy. Scientific Reports, 2017, 7, 43477.	1.6	41
111	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	0.9	38
112	Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2017, 76, 270-288.	0.9	98
113	ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e335.	3.1	65
114	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	1.1	87
115	Globular glial inclusions unveil enigmas of <scp>MAPT</scp> mutations. Neuropathology and Applied Neurobiology, 2017, 43, 191-193.	1.8	1
116	17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression. Molecular Psychiatry, 2017, 22, 1119-1125.	4.1	57
117	Novel approach for accurate tissue-based protein colocalization and proximity microscopy. Scientific Reports, 2017, 7, 2668.	1.6	16
118	Protein astrogliopathies in human neurodegenerative diseases and aging. Brain Pathology, 2017, 27, 675-690.	2.1	68
119	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathologyâ€based cohort. European Journal of Neurology, 2017, 24, 1326.	1.7	71
120	Differential overexpression of SERPINA3 in human prion diseases. Scientific Reports, 2017, 7, 15637.	1.6	58
121	Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome: a morphological and molecular dilemma. Brain, 2017, 140, e51-e51.	3.7	43
122	Novel AARS2 gene mutation producing leukodystrophy: a case report. Journal of Human Genetics, 2017, 62, 329-333.	1.1	29
123	Tau pathology in Creutzfeldtâ€Jakob disease revisited. Brain Pathology, 2017, 27, 332-344.	2.1	61
124	Sexually Dimorphic Expression of Reelin in the Brain of a Mouse Model of Alzheimer Disease. Journal of Molecular Neuroscience, 2017, 61, 359-367.	1.1	7
125	GABAA receptor subunit deregulation in the hippocampus of human foetuses with Down syndrome. Brain Structure and Function, 2017, 223, 1501-1518.	1.2	8
126	Introduction. Brain Pathology, 2017, 27, 627-628.	2.1	1

#	Article	IF	Citations
127	Cross-seeding of prions by aggregated Î±-synuclein leads to transmissible spongiform encephalopathy. PLoS Pathogens, 2017, 13, e1006563.	2.1	42
128	Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease. Current Alzheimer Research, 2017, 14, 1305-1317.	0.7	69
129	Affection of the Respiratory Muscles in Combined Complex I and IV Deficiency. The Open Neurology Journal, 2017, 11, 1-6.	0.4	2
130	Psoriasis, bulbar involvement, and diarrhea in late myoclonic epilepsy with ragged-red fibers-syndrome due to the m.8344A > G tRNA (Lys) mutation. Iranian Journal of Neurology, 2017, 16, 45-49.	0.5	5
131	Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease. Frontiers in Aging Neuroscience, 2016, 8, 163.	1.7	86
132	Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. International Journal of Molecular Sciences, 2016, 17, 189.	1.8	223
133	Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathologica, 2016, 132, 531-543.	3.9	173
134	Dura mater is a potential source of AÎ² seeds. Acta Neuropathologica, 2016, 131, 911-923.	3.9	85
135	Deposition of C-terminally truncated AÎ² species AÎ²37 and AÎ²39 in Alzheimerâ€™s disease and transgenic mouse models. Acta Neuropathologica Communications, 2016, 4, 24.	2.4	29
136	Familial early-onset dementia with complex neuropathologic phenotype and genomic background. Neurobiology of Aging, 2016, 42, 199-204.	1.5	16
137	Shared and Distinct Patterns of Oligodendroglial Response in Î±-Synucleinopathies and Tauopathies. Journal of Neuropathology and Experimental Neurology, 2016, 75, 1100-1109.	0.9	35
138	Can Creutzfeldt-Jakob disease unravel the mysteries of Alzheimer?. Prion, 2016, 10, 369-376.	0.9	6
139	Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia. Neuropathology, 2016, 36, 27-38.	0.7	26
140	Lack of age-related clinical progression in PGC-1Î±-deficient mice â€“ implications for mitochondrial encephalopathies. Behavioural Brain Research, 2016, 313, 272-281.	1.2	11
141	Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain, 2016, 139, 3237-3252.	3.7	107
142	Post-mortem assessment in vascular dementia: advances and aspirations. BMC Medicine, 2016, 14, 129.	2.3	99
143	The Î±1, Î±2, Î±3, and Î²2 subunits of GABA_A receptors show characteristic spatial and temporal expression patterns in rhombencephalic structures during normal human brain development. Journal of Comparative Neurology, 2016, 524, 1805-1824.	0.9	20
144	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	3.9	380

#	Article	IF	Citations
145	Comparative anatomical distribution of neuronal calcium-binding protein (NECAB) 1 and -2 in rodent and human spinal cord. Brain Structure and Function, 2016, 221, 3803-3823.	1.2	14
146	A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases. Molecular Neurodegeneration, 2016, 11, 11.	4.4	14
147	Amyloid-Î² pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Medical Weekly, 2016, 146, w14287.	0.8	89
148	Histopathological comparison of Kearns-Sayre syndrome and PGC-1Î±-deficient mice suggests aÂnovel concept for vacuole formation in mitochondrial encephalopathy. Folia Neuropathologica, 2016, 1, 9-22.	0.5	15
149	Gaucher cells are not associated with Î±-synuclein neuropathology in infants. , 2016, 35, 122-128.		4
150	Clinical Neuropathology image 1-2015: Crystal-storing histiocytosis of the central nervous system. , 2015, 34, 4-5.		6
151	Pathological and biochemical investigation of a woman diagnosed with genetic <scp>C</scp>reutzfeldtâ€“<scp>J</scp>akob disease shortly after parturition. Neuropathology and Applied Neurobiology, 2015, 41, 676-680.	1.8	0
152	Patterns of Tau and Î±-Synuclein Pathology in the Visual System. Journal of Parkinson's Disease, 2015, 5, 333-340.	1.5	15
153	Progressive Dopamine Transporter Binding Loss in Autopsy-Confirmed Corticobasal Degeneration. Journal of Parkinson's Disease, 2015, 5, 907-912.	1.5	22
154	I716F AÎ²PP Mutation Associates with the Deposition of Oligomeric Pyroglutamate Amyloid-Î² and Î±-Synucleinopathy with Lewy Bodies. Journal of Alzheimer's Disease, 2015, 44, 103-114.	1.2	13
155	Case report Adult, isolated respiratory chain complex IV deficiency with minimal manifestations. Folia Neuropathologica, 2015, 2, 153-157.	0.5	3
156	Neuropeptide S- and Neuropeptide S receptor-expressing neuron populations in the human pons. Frontiers in Neuroanatomy, 2015, 9, 126.	0.9	31
157	A Genome Wide Association Study Links Glutamate Receptor Pathway to Sporadic Creutzfeldt-Jakob Disease Risk. PLoS ONE, 2015, 10, e0123654.	1.1	28
158	Genetic Creutzfeldt-Jakob disease mimicking chronic inflammatory demyelinating polyneuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e173.	3.1	5
159	Bilateral Dentate Gyrus Structural Alterations in a Cat Associated With Hippocampal Sclerosis and Intraventricular Meningioma. Veterinary Pathology, 2015, 52, 1183-1186.	0.8	11
160	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. Journal of Neural Transmission, 2015, 122, 957-972.	1.4	25
161	Association of Cerebrospinal Fluid Prion Protein Levels and the Distinction Between Alzheimer Disease and Creutzfeldt-Jakob Disease. JAMA Neurology, 2015, 72, 267.	4.5	69
162	A case of variably protease-sensitive prionopathy treated with doxycyclin. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 816-818.	0.9	23

#	Article	IF	Citations
163	Screening for Î±-synuclein immunoreactive neuronal inclusions in the hippocampus allows identification of atypical MSA (FTLD-synuclein). Acta Neuropathologica, 2015, 130, 299-301.	3.9	22
164	Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimerâ€™s disease. Acta Neuropathologica, 2015, 129, 541-563.	3.9	36
165	Atypical sporadic <scp>CJDâ€MM</scp> phenotype with white matter kuru plaques associated with intranuclear inclusion body and argyrophilic grain disease. Neuropathology, 2015, 35, 336-342.	0.7	11
166	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathologica, 2015, 129, 757-762.	3.9	139
167	Heroin abuse exaggerates age-related deposition of hyperphosphorylated tau and p62-positive inclusions. Neurobiology of Aging, 2015, 36, 3100-3107.	1.5	54
168	Invited review: Neuropathology of tauopathies: principles and practice. Neuropathology and Applied Neurobiology, 2015, 41, 3-23.	1.8	405
169	Creutzfeldtâ€“Jakob Disease and Dementia. , 2015, , 45-55.		0
170	Clinical Neuropathology teaching case 4-2015: Heterogenous brain pathologies temporally and spatially coinciding in limbic regions. , 2015, 34, 178-180.		0
171	Detection of disease-associated ÃŽÂ±-synuclein in the cerebrospinal fluid: a feasibility study. , 2014, 33, 329-334.		19
172	Î±<scp>B</scp>â€crystallin and <scp>HSP27</scp> in glial cells in tauopathies. Neuropathology, 2014, 34, 517-526.	0.7	16
173	Oligodendroglial Response in the Spinal Cord in TDP-43 Proteinopathy with Motor Neuron Involvement. Neurodegenerative Diseases, 2014, 14, 117-124.	0.8	23
174	Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1386-1395.	0.9	280
175	Prevalence of mixed pathologies in the aging brain. Alzheimer's Research and Therapy, 2014, 6, 82.	3.0	232
176	mTOR Hyperactivation in Down Syndrome Hippocampus Appears Early During Development. Journal of Neuropathology and Experimental Neurology, 2014, 73, 671-683.	0.9	66
177	Patterns of Hippocampal Tau Pathology Differentiate Neurodegenerative Dementias. Dementia and Geriatric Cognitive Disorders, 2014, 38, 375-388.	0.7	28
178	Glial and Neuronal Tau Pathology in Tauopathies. Journal of Neuropathology and Experimental Neurology, 2014, 73, 81-97.	0.9	174
179	Cerebrotendinous xanthomatosis with the c.379<scp>C</scp>><scp>T</scp> (p.<scp>R</scp>127<scp>W</scp>) mutation in the <scp>CYP27A1</scp> gene associated with premature ageâ€associated limbic tauopathy. Neuropathology and Applied Neurobiology, 2014, 40, 345-350.	1.8	14
180	Linking pathways in the developing and aging brain with neurodegeneration. Neuroscience, 2014, 269, 152-172.	1.1	56

#	Article	IF	Citations
181	Distinct Patterns of Sirtuin Expression During Progression of Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2014, 16, 405-414.	1.8	105
182	Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Movement Disorders, 2014, 29, 1767-1773.	2.2	108
183	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	3.9	1,060
184	Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. Nature Communications, 2014, 5, 4421.	5.8	70
185	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93
186	Loss of Calbindin immunoreactivity in the dentate gyrus distinguishes Alzheimer's disease from other neurodegenerative dementias. Neuroscience Letters, 2014, 566, 137-141.	1.0	18
187	Intracellular processing of disease-associated Î±-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiology of Disease, 2014, 69, 76-92.	2.1	110
188	Practical approach to diagnosis. , 2014, , 55-69.		3
189	Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes. Current Alzheimer Research, 2014, 11, 694-705.	0.7	24
190	Clinical Neuropathology image 6-2014: Corpora amylacea replacing cornu ammonis (CACA). , 2014, 33, 378-379.		2
191	Clinical Neuropathology image 5-2014: ÃŽÂ±-synuclein pathology in the ependyma in ParkinsonÃ¢Â€Â™s disease. , 2014, 33, 328.		2
192	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration. , 2014, , 209-248.		3
193	Tauopathies. , 2014, , 109-148.		1
194	Synucleinopathies. , 2014, , 149-175.		0
195	Neurodegenerative diseases linked to trinucleotide repeats. , 2014, , 195-208.		2
196	Other neurodegenerative conditions I. , 2014, , 249-258.		0
197	Concomitant pathologies I. , 2014, , 274-291.		0
198	Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathologica, 2013, 126, 365-384.	3.9	264

#	Article	IF	Citations
199	Developmental patterns of DR6 in normal human hippocampus and in Down syndrome. Journal of Neurodevelopmental Disorders, 2013, 5, 10.	1.5	9
200	Cerebellar dysfunction in a family harboring the PSEN1 mutation co-segregating with a Cathepsin D variant p.A58V. Journal of the Neurological Sciences, 2013, 326, 75-82.	0.3	18
201	Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathologica, 2013, 126, 537-544.	3.9	168
202	N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta Neuropathologica Communications, 2013, 1, 56.	2.4	36
203	Rapidly progressive dementia with thalamic degeneration and peculiar cortical prion protein immunoreactivity, but absence of proteinase K resistant PrP: a new disease entity?. Acta Neuropathologica Communications, 2013, 1, 72.	2.4	12
204	A Panâ€‹scp›E‹/scp›uropean Study of the‹i›C9orf72‹/i›Repeat Associated with‹scp›FTLD‹/scp›: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	1.1	247
205	Left ventricular hypertrabeculation/noncompaction coincidentally found in sporadic inclusion body myositis. International Journal of Cardiology, 2013, 168, 610-612.	0.8	5
206	Nonâ€neuronal cell responses differ between normal and Down syndrome developing brains. International Journal of Developmental Neuroscience, 2013, 31, 796-803.	0.7	30
207	Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration. Parkinsonism and Related Disorders, 2013, 19, 222-226.	1.1	23
208	Protein kinase CÎ³ antibodies and paraneoplastic cerebellar degeneration. Journal of Neuroimmunology, 2013, 256, 91-93.	1.1	23
209	Atypical and Classical Forms of the Disease-Associated State of the Prion Protein Exhibit Distinct Neuronal Tropism, Deposition Patterns, and Lesion Profiles. American Journal of Pathology, 2013, 183, 1539-1547.	1.9	26
210	Neuropathology of the hippocampus in FTLDâ€Tau with Pick bodies: a study of the BrainNet Europe Consortium. Neuropathology and Applied Neurobiology, 2013, 39, 166-178.	1.8	54
211	Endonuclease G mediates Î±-synuclein cytotoxicity during Parkinson's disease. EMBO Journal, 2013, 32, 3041-3054.	3.5	71
212	Intensity of human prion disease surveillance predicts observed disease incidence. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1372-1377.	0.9	49
213	Asymptomatic hyper-creatine-kinase-emia as sole manifestation of inclusion body myositis. Neurology International, 2013, 5, 11.	1.3	6
214	Adult mitochondrial DNA depletion syndrome with mild manifestations. Neurology International, 2013, 5, 9.	1.3	7
215	Neuropathology of Partial PGC-1Î± Deficiency Recapitulates Features of Mitochondrial Encephalopathies but Not of Neurodegenerative Diseases. Neurodegenerative Diseases, 2013, 12, 177-188.	0.8	17
216	The Spectrum of Tau Pathology in Human Prion Disease. , 2013, , 103-119.		6

#	Article	IF	Citations
217	Incidental corticobasal degeneration in a 76-year-old woman. , 2013, 32, 69-72.		16
218	Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis. Clinical Chemistry, 2012, 58, 787-789.	1.5	50
219	Stabilization of a Prion Strain of Synthetic Origin Requires Multiple Serial Passages. Journal of Biological Chemistry, 2012, 287, 30205-30214.	1.6	51
220	Intraneuronal Immunoreactivity for the Prion Protein Distinguishes a Subset of E200K Genetic From Sporadic Creutzfeldt-Jakob Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 223-232.	0.9	18
221	Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-Î² in a Fraction of Amyloid-Î² Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates. Journal of Alzheimer's Disease, 2012, 29, 361-371.	1.2	17
222	Novel crystalloid oligodendrogliopathy in hereditary spastic paraplegia. Acta Neuropathologica, 2012, 124, 583-591.	3.9	8
223	Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathologica, 2012, 124, 517-529.	3.9	184
224	The need to unify neuropathological assessments of vascular alterations in the ageing brain. Experimental Gerontology, 2012, 47, 825-833.	1.2	57
225	Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes. Journal of Alzheimer's Disease, 2012, 31, 13-20.	1.2	94
226	A New Mechanism for Transmissible Prion Diseases. Journal of Neuroscience, 2012, 32, 7345-7355.	1.7	72
227	[125I]SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimerâ€™s disease. Neurochemistry International, 2012, 60, 286-291.	1.9	36
228	Impaired myelination of the human hippocampal formation in Down syndrome. International Journal of Developmental Neuroscience, 2012, 30, 147-158.	0.7	75
229	Clinical stratification of subtypes of Alzheimer's disease. Lancet Neurology, The, 2012, 11, 839-841.	4.9	10
230	Genetic Creutzfeldtâ€“Jakob disease with R208H mutation presenting as progressive supranuclear palsy. Movement Disorders, 2012, 27, 476-479.	2.2	25
231	Nigral Tau pathology and striatal amyloid-Î² deposition does not correlate with striatal dopamine deficit in Alzheimerâ€™s disease. Journal of Neural Transmission, 2012, 119, 1545-1549.	1.4	4
232	An antibody with high reactivity for disease-associated Î±-synuclein reveals extensive brain pathology. Acta Neuropathologica, 2012, 124, 37-50.	3.9	133
233	Pellagra encephalopathy as a differential diagnosis for Creutzfeldt-Jakob disease. Metabolic Brain Disease, 2012, 27, 231-235.	1.4	5
234	Extranodal marginal zone lymphoma of the CNS arising after a long-standing history of atypical white matter disease. Leukemia Research, 2012, 36, e155-e157.	0.4	10

#	Article	IF	Citations
235	Dopamine transporter imaging in autopsyâ€confirmed Parkinson's disease and multiple system atrophy. Movement Disorders, 2012, 27, 65-71.	2.2	72
236	Asymmetry of neurodegenerative disease-related pathologies: a cautionary note. Acta Neuropathologica, 2012, 123, 449-452.	3.9	35
237	Health professions and risk of sporadic Creutzfeldtâ€"Jakob disease, 1965 to 2010. Eurosurveillance, 2012, 17, .	3.9	24
238	Clinical Neuropathology Practice News 3-2012: the Â"ABCÂ" in ADÂÂ–Ârevised and updated guideline for the neuropathologic assessment of AlzheimerÂ's disease. , 2012, 31, 116-118.		8
239	Prominent oligodendroglial response in surgical specimens of patients with temporal lobe epilepsy. , 2012, 31, 409-417.		34
240	Long-term clinical improvement of progressive multifocal leukoencephalopathy associated with prominent inflammatory response and follicular lymphoma. Leukemia and Lymphoma, 2011, 52, 2190-2192.	0.6	0
241	Molecular diagnosis of human prion disease. Expert Opinion on Medical Diagnostics, 2011, 5, 291-306.	1.6	12
242	Low ambient temperature reveals distinct mechanisms for MDMA-induced serotonergic toxicity and astroglial Hsp27 heat shock response in rat brain. Neurochemistry International, 2011, 59, 695-705.	1.9	5
243	Layer-specific activity of tissue non-specific alkaline phosphatase in the human neocortex. Neuroscience, 2011, 172, 406-418.	1.1	51
244	New lexicon and criteria for the diagnosis of Alzheimer's disease. Lancet Neurology, The, 2011, 10, 298-299.	4.9	26
245	Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy. Acta Neuropathologica, 2011, 121, 39-57.	3.9	105
246	A peculiar constellation of tau pathology defines a subset of dementia in the elderly. Acta Neuropathologica, 2011, 122, 205-222.	3.9	80
247	Peroxisomal alterations in Alzheimerâ€™s disease. Acta Neuropathologica, 2011, 122, 271-283.	3.9	176
248	Clinico-pathological correlations in neurodegeneration. Acta Neuropathologica, 2011, 122, 115-116.	3.9	5
249	Complex tauopathies vs. tangle predominant dementia. Acta Neuropathologica, 2011, 122, 517-517.	3.9	0
250	Ultrastructural characterization of tryptophan hydroxylase 2-specific cortical serotonergic fibers and dorsal raphe neuronal cell bodies after MDMA treatment in rat. Psychopharmacology, 2011, 213, 377-391.	1.5	21
251	FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP-43 proteinopathies. A report of three cases. BMC Neurology, 2011, 11, 50.	0.8	25
252	Recovery and aging of serotonergic fibers after single and intermittent MDMA treatment in dark agouti rat. Journal of Comparative Neurology, 2011, 519, 2353-2378.	0.9	18

#	Article	IF	Citations
253	Prion diseases: a primer for general pathologists. Diagnostic Histopathology, 2011, 17, 217-224.	0.2	2
254	Fatal Prion Disease in a Mouse Model of Genetic E200K Creutzfeldt-Jakob Disease. PLoS Pathogens, 2011, 7, e1002350.	2.1	68
255	Genesis of Mammalian Prions: From Non-infectious Amyloid Fibrils to a Transmissible Prion Disease. PLoS Pathogens, 2011, 7, e1002419.	2.1	98
256	Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7. , 2011, 30, 3-10.		35
257	Curcumin Labeling of Neuronal Fibrillar Tau Inclusions in Human Brain Samples. Journal of Neuropathology and Experimental Neurology, 2010, 69, 405-414.	0.9	46
258	Cathepsin D (C224T) Polymorphism in Sporadic and Genetic Creutzfeldt-Jakob Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 104-107.	0.6	12
259	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	3.9	854
260	Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathologica, 2010, 119, 177-187.	3.9	256
261	Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathologica, 2010, 119, 389-408.	3.9	98
262	Distribution of apoptosis-related proteins in sporadic Creutzfeldtâ€“Jakob disease. Brain Research, 2010, 1323, 192-199.	1.1	17
263	Tubulin polymerization promoting protein (TPPP/p25) as a marker for oligodendroglial changes in multiple sclerosis. Glia, 2010, 58, 1847-1857.	2.5	61
264	Production of a monoclonal antibody, against human Î±-synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the Î±-synuclein locus. Journal of Neuroscience Methods, 2010, 192, 268-276.	1.3	11
265	Rapid Progression of Amyotrophic Lateral Sclerosis in an Acromegalic Patient After Surgical Resection of a Growth Hormone-Producing Pituitary Adenoma. Neurologist, 2010, 16, 315-318.	0.4	4
266	Ultrastructural Characteristics (or Evaluation) of Creutzfeldt-Jakob Disease and Other Human Transmissible Spongiform Encephalopathies or Prion Diseases. Ultrastructural Pathology, 2010, 34, 351-361.	0.4	30
267	Acute SSRI-induced anxiogenic and brain metabolic effects are attenuated 6 months after initial MDMA-induced depletion. Behavioural Brain Research, 2010, 207, 280-289.	1.2	14
268	Increased neuronal Rab5 immunoreactive endosomes do not colocalize with TDP-43 in motor neuron disease. Experimental Neurology, 2010, 225, 133-139.	2.0	10
269	Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. , 2010, 29, 271-288.		68
270	Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy. Central Nervous System Agents in Medicinal Chemistry, 2009, 9, 2-11.	0.5	11

#	Article	IF	Citations
271	Molecular Pathology of Human Prion Diseases. International Journal of Molecular Sciences, 2009, 10, 976-999.	1.8	73
272	Genetic Creutzfeldt-Jakob disease mimicking variant Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1410-1411.	0.9	5
273	TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Movement Disorders, 2009, 24, 1842-1847.	2.2	182
274	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica, 2009, 117, 15-18.	3.9	377
275	Assessment of Î²-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	3.9	143
276	Staging/typing of Lewy body related Î±-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	3.9	249
277	Protein-Based Neuropathology and Molecular Classification of Human Neurodegenerative Diseases. Focus on Structural Biology, 2009, , 251-272.	0.1	5
278	MAPT S305I mutation: implications for argyrophilic grain disease. Acta Neuropathologica, 2008, 116, 103-118.	3.9	52
279	Inter-laboratory comparison of neuropathological assessments of Î²-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 533-546.	3.9	86
280	Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 497-507.	3.9	101
281	Cathepsin D SNP associated with increased risk of variant Creutzfeldt-Jakob disease. BMC Medical Genetics, 2008, 9, 31.	2.1	19
282	Nigral burden of Î±â€synuclein correlates with striatal dopamine deficit. Movement Disorders, 2008, 23, 1608-1612.	2.2	53
283	Increased glucose metabolism and ATP level in brain tissue of Huntingtonâ€™s disease transgenic mice. FEBS Journal, 2008, 275, 4740-4755.	2.2	60
284	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	2.1	361
285	Prion Diseases: From Protein to Cell Pathology. American Journal of Pathology, 2008, 172, 555-565.	1.9	126
286	Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience. Dementia and Geriatric Cognitive Disorders, 2008, 26, 343-350.	0.7	148
287	Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2008, 366, 3599-3617.	1.6	13
288	Assessment of Î±-Synuclein Pathology: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2008, 67, 125-143.	0.9	73

#	Article	IF	Citations
289	White Matter Tauopathy With Globular Glial Inclusions: A Distinct Sporadic Frontotemporal Lobar Degeneration. Journal of Neuropathology and Experimental Neurology, 2008, 67, 963-975.	0.9	111
290	Excretion of Transmissible Spongiform Encephalopathy Infectivity in Urine. Emerging Infectious Diseases, 2008, 14, 1406-1412.	2.0	46
291	Heroin Abuse Is Characterized by Discrete Mesolimbic Dopamine and Opioid Abnormalities and Exaggerated Nuclear Receptor-Related 1 Transcriptional Decline with Age. Journal of Neuroscience, 2007, 27, 13371-13375.	1.7	36
292	X-linked Hyper-IgM Syndrome Associated With a Rapid Course of Multifocal Leukoencephalopathy. Archives of Neurology, 2007, 64, 273.	4.9	17
293	Involvement of the Endosomal-Lysosomal System Correlates With Regional Pathology in Creutzfeldt-Jakob Disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 628-636.	0.9	68
294	Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord. Neuropathology and Applied Neurobiology, 2007, 33, 193-203.	1.8	27
295	How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. Journal of Neural Transmission, 2007, 114, 527-537.	1.4	49
296	The brain-specific protein TPPP/p25 in pathological protein deposits of neurodegenerative diseases. Acta Neuropathologica, 2007, 113, 153-161.	3.9	65
297	TPPP/p25 in brain tumours: expression in non-neoplastic oligodendrocytes but not in oligodendroglioma cells. Acta Neuropathologica, 2007, 113, 213-215.	3.9	28
298	Interaction of TPPP/p25 protein with glyceraldehyde-3-phosphate dehydrogenase and their co-localization in Lewy bodies. FEBS Letters, 2006, 580, 5807-5814.	1.3	34
299	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	0.9	95
300	Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in Dark Agouti rat: Temporal, spatial, and cellular patterns. Journal of Comparative Neurology, 2006, 497, 251-269.	0.9	38
301	Subcellular Distribution of Components of the Ubiquitin-Proteasome System in Non-diseased Human and Rat Brain. Journal of Histochemistry and Cytochemistry, 2006, 54, 263-267.	1.3	25
302	Acquired Neuromyotonia Precipitated by Thyroid Surgery and Associated with Antiacetylcholine Receptor Antibodies. European Neurology, 2006, 55, 222-224.	0.6	0
303	Prion disease with a 144 base pair insertion: unusual cerebellar prion protein immunoreactivity. Acta Neuropathologica, 2005, 110, 513-519.	3.9	23
304	Genetic prion disease: the EUROCJD experience. Human Genetics, 2005, 118, 166-174.	1.8	391
305	Increased incidence of genetic human prion disease in Hungary. Neurology, 2005, 65, 1666-1669.	1.5	12
306	The ubiquitinâ€“proteasome system in Creutzfeldtâ€“Jakob and Alzheimer disease: Intracellular redistribution of components correlates with neuronal vulnerability. Neurobiology of Disease, 2005, 19, 427-435.	2.1	20

#	Article	IF	Citations
307	Calretinin-immunoreactive unipolar brush cells in the developing human cerebellum. International Journal of Developmental Neuroscience, 2005, 23, 723-729.	0.7	14
308	Subcellular Localization of Disease-Associated Prion Protein in the Human Brain. American Journal of Pathology, 2005, 166, 287-294.	1.9	77
309	Rationale for diagnosing human prion disease. World Journal of Biological Psychiatry, 2004, 5, 83-91.	1.3	10
310	TPPP/p25: from unfolded protein to misfolding disease: prediction and experiments. Biology of the Cell, 2004, 96, 701-711.	0.7	56
311	Increased 14-3-3 immunoreactivity in glial elements in patients with multiple sclerosis. Acta Neuropathologica, 2004, 107, 137-143.	3.9	19
312	The prion protein in human neuromuscular diseases. Journal of Pathology, 2004, 204, 241-247.	2.1	19
313	Creutzfeldt-Jakob disease and inclusion body myositis: Abundant disease-associated prion protein in muscle. Annals of Neurology, 2004, 55, 121-125.	2.8	47
314	Neuropathology of white matter disease in Leber's hereditary optic neuropathy. Brain, 2004, 128, 35-41.	3.7	96
315	Complement activation in human prion disease. Neurobiology of Disease, 2004, 15, 21-28.	2.1	68
316	Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. Neurobiology of Disease, 2004, 17, 155-162.	2.1	140
317	Contribution of neuropathology to the understanding of human prion disease. Folia Neuropathologica, 2004, 42 Suppl A, 69-76.	0.5	3
318	Distinctive cerebellar immunoreactivity for the prion protein in familial (E200K) Creutzfeldt-Jakob disease. Acta Neuropathologica, 2003, 105, 449-454.	3.9	25
319	Immunostaining for ubiquitin: efficient pretreatment. Neuropathology and Applied Neurobiology, 2003, 29, 174-177.	1.8	3
320	Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. NeuroReport, 2003, 14, 73-76.	0.6	69
321	Disease-Associated Prion Protein in Vessel Walls. American Journal of Pathology, 2002, 161, 1979-1984.	1.9	47
322	The prion protein in human neurodegenerative disorders. Neuroscience Letters, 2002, 329, 269-272.	1.0	44
323	Aging, the brain and human prion disease. Experimental Gerontology, 2002, 37, 603-605.	1.2	12
324	Î²-CIT SPECT demonstrates reduced availability of serotonin transporters in patients with Fatal Familial Insomnia. Journal of Neural Transmission, 2002, 109, 1105-1110.	1.4	29

#	Article	IF	Citations
325	Distribution of intraneuronal immunoreactivity for the prion protein in human prion diseases. Acta Neuropathologica, 2002, 104, 320-326.	3.9	19
326	Mutations of the Prion Protein Gene. Journal of Neurology, 2002, 249, 1567-1582.	1.8	251
327	Immunohistochemistry for the Prion Protein: Comparison of Different Monoclonal Antibodies in Human Prion Disease Subtypes. Brain Pathology, 2002, 12, 1-11.	2.1	96
328	Prominent Stress Response of Purkinje Cells in Creutzfeldtâ€“Jakob Disease. Neurobiology of Disease, 2001, 8, 881-889.	2.1	29
329	Serotonergic nuclei of the raphe are not affected in human ageing. NeuroReport, 2001, 12, 669-671.	0.6	18
330	Inherited prion disease with A117V mutation of the prion protein gene: a novel Hungarian family. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 802-805.	0.9	16
331	Clinicopathological phenotype of codon 129 valine homozygote sporadic Creutzfeldt-Jakob disease. Neuropathology and Applied Neurobiology, 2000, 26, 463-472.	1.8	42
332	Human prion diseases. , 0, , 176-194.		2
333	Clinical aspects of dementia. , 0, , 8-28.		0
334	Clinical aspects of movement disorders. , 0, , 29-50.		0
335	Ethical, health and safety considerations. , 0, , 51-54.		0
336	Molecular methods. , 0, , 70-79.		0
337	Other neurodegenerative conditions II. , 0, , 259-262.		0
338	Other neurogenerative conditions III. , 0, , 263-267.		0
339	Other neurogenerative conditions IV. , 0, , 268-273.		0
340	Concomitant pathologies II. , 0, , 292-298.		0